ClinicalTrials.gg
CompletedNCT03554772Updated Jan 22, 2021Results posted

Efficacy, Tolerability, Safety, and Pharmacokinetic Study of DFN-15

A Phase 2 interventional study of DFN-15 (Celecoxib Oral Solution) 62.5 mg and DFN-15 (Celecoxib Oral Solution) 125 mg in Acute Pain, sponsored by Dr. Reddy's Laboratories Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-01-22.

Sponsored by Dr. Reddy's Laboratories Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 351 studies in Acute Pain with a site in United States — 47 open to participants now, 53 under way, 1 of them phase 3. Acute Pain · United States.

Enrollment
117th of 320
120 · median 84
Started
2018
with 33 others
Phase 2
54 of 351
6 open now
Registered
137th of 351
by date

Among the 351 studies in Acute Pain with a site in United States, this one is the 117th largest by enrollment of the 320 interventional ones that give a count, is one of 34 that started in 2018, is one of 54 in phase 2, and was the 137th registered.

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.

Browse Acute Pain studies →

Open to participants now

47 of the 351 studies in Acute Pain with a site in United States are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 351 studies in Acute Pain with a site in United States, or all of them as a file.
02

Study summary

Efficacy, Tolerability, Safety and Pharmacokinetic Study of DFN-15 in Post-Surgical Dental Pain.

Read the detailed description

This is a Phase 2, single-center, randomized, double blind, dose-ranging placebo-controlled, clinical study evaluating the efficacy, tolerability, safety, and the pharmacokinetic properties of a known drug (selective COX-2 inhibitor) administered as an alternative formulation/dosage form (DFN-15, a liquid oral formulation) in an accepted model of acute post-operative pain (acute pain following oral surgery for extraction of bilateral impacted mandibular third molar teeth in otherwise healthy subjects).120 female and male healthy subjects scheduled to undergo elective bilateral third molar extraction will be randomized, after they provide informed consent and are confirmed to meet all the study selection criteria, in a 1:1:1:1 ratio to receive a single oral dose of either DFN-15 Dose A DFN-15 Dose B, DFN-15 Dose C or matching placebo.

Subjects will undergo a screening procedure (within 28 days of the scheduled extraction of the impacted third molars) that will involve the collection of demographic information, height, weight and body mass index (BMI), urine pregnancy test (women of child-bearing potential,) medical and medicinal history, physical examination, dental examination, vital signs measurement (blood pressure, pulse rate, respiratory rate), clinical laboratory investigation (hematology,serology, coagulation parameters, serum chemistry and urinalysis),12-lead ECG and a panoramic x-ray to document the impacted mandibular third molar teeth. As a pre-requisite for randomization, subjects will be required to report "moderate" to "severe" baseline pain on the provided paper diary within 6 hours post-surgery (called the 'Baseline' period) as characterized on a 4-point categorical pain intensity (PI) scale (0= none, 1= mild, 2= moderate, 3= severe), and a score of ≥5, on the 11-point Numerical Pain Rating Scale (NPRS) where 0 represents 'no pain' and 10 represents 'worst pain imaginable'. Eligible subjects will be randomized and will receive a single dose of the assigned study treatment. Subjects will be randomized and administered the study medication within 15 minutes of meeting the post-operative inclusion criteria (baseline score).Subjects will be assessed at pre-specified time-points over an observation period of 8 hours from the time of randomization.

Subjects with inadequately controlled pain symptoms may request rescue analgesic medication. Subjects will be encouraged to delay using the rescue medication if their pain is tolerable until 120 minutes post-dose of study medication. A subject who is administered rescue pain medication will continue completing pain assessments until 8 hours after treatment initiation. All randomized subjects will be provided with a paper diary to record pain assessments (Pain Intensity on 11-point NPRS scale, followed by Pain Relief using a 5-point categorical scale [where 0= no pain relief, 1= little pain relief, 2= some pain relief, 3= a lot of pain relief, 4= complete pain relief]) At study medication administration, two stopwatches will be started, to measure times to 'perceptible' and 'meaningful' pain-relief. Subjects will be instructed to stop the first stopwatch when they first perceive pain relief to occur (time to perceptible relief). Subjects will be instructed to stop the second stopwatch when they first experience meaningful pain relief (time to meaningful relief). Stopwatch times of perceptible relief and meaningful relief will be recorded using exact stopwatch time displayed.

In addition, at 8 hours post-dose or within 5 minutes prior to first use of rescue medication (whichever is earlier), subjects will be asked to record within the provided patient diary: 'Patient Rating of Treatment Satisfactoriness' using a 5-point verbal rating scale (0 =poor, 1 =fair, 2 =good, 3=very good, 4 =excellent).

Subjects will remain NPO (nothing by mouth), including water, from Check-in (i.e., at least 2 hours before the administration of the dose of study medication to randomized subjects) until 2 hours post-dose, on Day 1 (study day). After 2 hours post-dose, subjects may be permitted to consume water, or gelatin snacks. Subjects are prohibited from ingesting solid foods or carbonated beverages for at least 6 hours post-dose.

12-lead ECG and Vital Signs were performed before surgery, at baseline and at periodic intervals post-dose until 8 hours .At discharge (8 hours post-randomization) from the clinical facility, all AEs reported for the subjects will be reviewed. A physical examination, including evaluation of the incision site for hematomas, and clinical laboratory evaluation (coagulation parameters and specific hematology, serum biochemistry and urinalysis parameters) will be conducted.

All subjects will have blood drawn at specified time points (pre-dose and over the 8 hour observation period) for pharmacokinetic evaluation.

Subjects will return to the research center 7 days (± 3 days) post-surgery for evaluation of their safety and well-being. Any AEs experienced post-surgery will be reviewed. A physical examination, of the subject will be performed, 12-lead ECG, and vital signs parameters will be repeated. Hematology, coagulation parameters, serum biochemistry and urinalysis parameters will be repeated only if there is a clinically significant abnormality or ongoing AE(s). Any changes to the prior and concomitant medication made after discharge will be reviewed and recorded.

03

Conditions studied

  • Acute Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects scheduled to undergo elective bilateral lower (mandibular) third molar extraction under local anesthesia.
  2. Subjects must be generally healthy, ambulatory, able to understand and willing to comply with study procedures, study restrictions, assessments, and requirements per the discretion of the investigator.
  3. Subjects must voluntarily sign written prior to any study-specific procedures.
  4. Subjects must have a (BMI) greater than or equal to 19.0 to less than or equal to 35.0

Exclusion criteria

Exclusion Criteria:

  1. History of migraine or frequent headaches, low back pain, or other acute or chronic pain conditions.
  2. Acute illness or unresolved local infection prior to surgery that can interfere with the conduct of the study.
  3. Positive results on urine drug screen or alcohol breath test indicative of illicit drug (Cocaine Metabolites, Marijuana (THC), MDMA (Ecstasy) and Phencyclidine) or alcohol abuse at screening and/or prior to extraction procedure.
  4. Positive results for the following (prescription included): Amphetamines, Barbiturates, Benzodiazepines, Methadone, Methamphetamine, Opiates, Oxycodone, and Tricyclic Antidepressants.
  5. Frequent use of nicotine-containing products.
  6. Excessive intake of caffeine-containing foods or beverages within 48 hours prior to surgery.
  7. Routinely uses pain medication.
  8. Currently taking any chronically (except for an inhaled steroid for pulmonary disease, and local topical or ophthalmic steroid) or has taken systemic corticosteroids within 4 weeks of the proposed date of surgery.
  9. Currently taking central nervous system active drugs such as hypnotics, sedatives, monoamine oxidase inhibitors, sympathomimetic amines, benzodiazepines, tricyclic antidepressants, or serotonin norepinephrine reuptake inhibitors, and anticonvulsants for pain.
  10. Donated blood products or had blood loss greater than 500 mL 30 days prior to Screening or between Screening and surgery.
  11. Member or relative of study staff or the Sponsor directly involved in the study.
  12. Previous participation in this study.
  13. Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within 30 days prior to the Screening visit.
  14. Currently receiving or have received within 7 days prior to product administration in the study, any drug (s) that is metabolized by hepatic microsomal enzyme CYP 2D6.
  15. disease or disorder which may put the subject at risk, influence the results or the subject's ability to participate in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    DFN-15 (Celecoxib Oral Solution) 62.5 mg

    Single dose containing 62.5 mg of celecoxib in 10 ml solution

    Drug: DFN-15 (Celecoxib Oral Solution) 62.5 mg

  • Experimental
    DFN-15 (Celecoxib Oral Solution) 125 mg

    Single dose containing 125 mg of celecoxib in 10 ml solution

    Drug: DFN-15 (Celecoxib Oral Solution) 125 mg

  • Experimental
    DFN-15 (Celecoxib Oral Solution) 250 mg

    Single dose containing 250 mg of celecoxib in 10 ml solution

    Drug: DFN-15 (Celecoxib Oral Solution) 250 mg

  • Placebo comparator
    Placebo

    Single dose containing 0 mg of celecoxib in 10 ml solution

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Summed Pain Intensity Difference Over the First Six Hours

    The primary endpoint is the Summed Pain Intensity Difference over the first 6 hours (SPID6) after dosing compared between DFN-15 and placebo. Pain intensity (P) will be measured at timepoints of 15, 30, and 45 minutes and 1, 1.5, 2, 3, 4, 5 and 6, hours after baseline ,using 11-point Pain Intensity Numerical Rating Scale (NPRS). Zero (0) equals no pain and Ten (10) equals worst pain imaginable. SPID6 is created by summing the time weighted pain intensity differences (PID) scores using the area under the PID curve methodology. All SPID calculations will be performed using the standard trapezoidal rule SPIDx =∑_(i=0)\^x▒((〖PID〗_i+〖PID〗_(i+1))/2) \* (T_(i+1)- T_i ) Where: PID_i = P_i - PBL (Pain score at time i and Pain score at Baseline), and (T_i+1 - T_i) is the Time difference in minutes between time i and time i+1. Therefore, SPID6 values may theoretically range between a maximum score of 0 ( no improvement) and a minimum score of -3525 (best improvement)

    Time frame: 6 hours post dose

07

Results

Posted Jan 22, 2021

Participant flow

Participant flow — Overall Study
MilestonePlaceboDFN-15 (Celecoxib Oral Solution) 62.5 mgDFN-15 (Celecoxib Oral Solution) 125 mgDFN-15 (Celecoxib Oral Solution) 250 mg
Started30302931
Completed treatment period (8 hours post dose)30302931
Completed30302929
Not completed0002
Withdrew: Lost to follow-up0002

Outcome measures

PrimarySummed Pain Intensity Difference Over the First Six Hours

The primary endpoint is the Summed Pain Intensity Difference over the first 6 hours (SPID6) after dosing compared between DFN-15 and placebo. Pain intensity (P) will be measured at timepoints of 15, 30, and 45 minutes and 1, 1.5, 2, 3, 4, 5 and 6, hours after baseline ,using 11-point Pain Intensity Numerical Rating Scale (NPRS). Zero (0) equals no pain and Ten (10) equals worst pain imaginable. SPID6 is created by summing the time weighted pain intensity differences (PID) scores using the area under the PID curve methodology. All SPID calculations will be performed using the standard trapezoidal rule SPIDx =∑_(i=0)\^x▒((〖PID〗_i+〖PID〗_(i+1))/2) \* (T_(i+1)- T_i ) Where: PID_i = P_i - PBL (Pain score at time i and Pain score at Baseline), and (T_i+1 - T_i) is the Time difference in minutes between time i and time i+1. Therefore, SPID6 values may theoretically range between a maximum score of 0 ( no improvement) and a minimum score of -3525 (best improvement)

Time frame:
6 hours post dose
Reported as:
Mean · units on a scale
Summed Pain Intensity Difference Over the First Six Hours
units on a scalePlaceboDFN-15 (Celecoxib Oral Solution) 62.5 mgDFN-15 (Celecoxib Oral Solution) 125 mgDFN-15 (Celecoxib Oral Solution) 250 mg
Summed Pain Intensity Difference Over the First Six Hours-420.2 ± 716.42-1101.0 ± 570.74-1771.7 ± 646.10-1463.5 ± 727.28
Statistical analysis
  • Placebo vs DFN-15 (Celecoxib Oral Solution) 62.5 mg vs DFN-15 (Celecoxib Oral Solution) 125 mg vs DFN-15 (Celecoxib Oral Solution) 250 mg · ANCOVA · p = <0.0001 (p-value for each dose group vs placebo comparison)ANCOVA model included treatment as main effect , baseline NPRS and basline BMI as covariates P-value is Dunnett adjusted (individual treatment arms)

Adverse events

Collected over All AEs, whether volunteered, elicited, or noted on physical examination, and regardless of causality or seriousness, were assessed and recorded in the CRF beginning after administration of study drug through the final follow-up assessment (approximately 7 ± 3 days after the last study drug administration). Additionally, if the investigator became aware of the occurrence of an SAE within 30 days of the last visit, the SAE was reported.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/30 (0%)0/30 (0%)4/30 (13.3%)
DFN-15 (Celecoxib Oral Solution) 62.5 mg0/30 (0%)0/30 (0%)5/30 (16.7%)
DFN-15 (Celecoxib Oral Solution) 125 mg0/29 (0%)0/29 (0%)4/29 (13.8%)
DFN-15 (Celecoxib Oral Solution) 250 mg0/31 (0%)0/31 (0%)5/31 (16.1%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPlaceboDFN-15 (Celecoxib Oral Solution) 62.5 mgDFN-15 (Celecoxib Oral Solution) 125 mgDFN-15 (Celecoxib Oral Solution) 250 mg
NauseaGastrointestinal disorders1/302/301/291/31
Blood Bilirubin IncreasedInvestigations0/301/300/292/31
EpistaxisRespiratory, thoracic and mediastinal disorders0/300/300/292/31
DizzinessNervous system disorders1/300/301/290/31
Alveolar OsteitisInfections and infestations1/300/301/290/31
Wolff-Parkinson-White syndromeCardiac disorders0/300/301/290/31
VomitingGastrointestinal disorders1/301/300/291/31
Blood Creatinine increasedInvestigations1/300/300/290/31
Blood Urine PresentInvestigations0/301/300/290/31
Cardiac MurmurInvestigations0/301/300/290/31

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboDFN-15 (Celecoxib Oral Solution) 62.5 mgDFN-15 (Celecoxib Oral Solution) 125 mgDFN-15 (Celecoxib Oral Solution) 250 mgTotal
Mean19.9 ± 2.7019.6 ± 2.4519.2 ± 1.6420.5 ± 2.4519.8 ± 2.37
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDFN-15 (Celecoxib Oral Solution) 62.5 mgDFN-15 (Celecoxib Oral Solution) 125 mgDFN-15 (Celecoxib Oral Solution) 250 mgTotal
Female1614171360
Male1416121860
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboDFN-15 (Celecoxib Oral Solution) 62.5 mgDFN-15 (Celecoxib Oral Solution) 125 mgDFN-15 (Celecoxib Oral Solution) 250 mgTotal
Hispanic or Latino664723
Not Hispanic or Latino2424252497
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboDFN-15 (Celecoxib Oral Solution) 62.5 mgDFN-15 (Celecoxib Oral Solution) 125 mgDFN-15 (Celecoxib Oral Solution) 250 mgTotal
American Indian or Alaska Native00101
Asian01001
Native Hawaiian or Other Pacific Islander10203
Black or African American11002
White28262228104
More than one race01214
Unknown or Not Reported01225
BMI
BMI(kg/ m^2)PlaceboDFN-15 (Celecoxib Oral Solution) 62.5 mgDFN-15 (Celecoxib Oral Solution) 125 mgDFN-15 (Celecoxib Oral Solution) 250 mgTotal
Mean26.4 ± 4.1527.1 ± 5.0325.1 ± 4.1124.4 ± 4.4125.8 ± 4.51
Qualifying Baseline Categorical Pain Score
Qualifying Baseline Categorical Pain Score(Participants)PlaceboDFN-15 (Celecoxib Oral Solution) 62.5 mgDFN-15 (Celecoxib Oral Solution) 125 mgDFN-15 (Celecoxib Oral Solution) 250 mgTotal
0 = No Pain00000
1= Mild Pain00000
2= Moderate Pain813111244
3= Severe Pain2217181976
08

Study locations

1 site
  • Site 101
    Salt Lake City, Utah 84124, United States
09

References and documents

Publications

  • Singla N, Bertoch T, Shenoy S, Munjal S. Efficacy and safety of single-dose DFN-15 for treatment of acute postsurgical dental pain: a randomized, double-blind, placebo-controlled study. Pain. 2022 Jan 1;163(1):91-99. doi: 10.1097/j.pain.0000000000002312. PubMed 34252915 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Aug 2018, 2 months.

Results were first posted in Jan 2021, 2 years 5 months after primary completion. A results delay was requested in Sep 2019.

Of 40 phase 2 interventional studies under Acute Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2018
First posted
Jun 13, 2018
StartActual
Jun 19, 2018
Primary completionActual
Aug 20, 2018
CompletionActual
Aug 20, 2018
Results delay requested
Sep 9, 2019
Results first posted
Jan 22, 2021
Last update
Jan 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03554772
Responsible party
Sponsor
First posted
Jun 13, 2018
Start date
Jun 19, 2018
Primary completion
Aug 20, 2018
Completion
Aug 20, 2018
Results posted
Jan 22, 2021
Last update
Jan 22, 2021

Study contacts

Elimor Brand-Schieber, PhD
study director · Director-Clinical Development

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion